Introduction of biosimilar insulins in Europe (Q39368850)

5 November 2017

7 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

15 August 2020

27 October 2020

13 November 2020

Introduction of biosimilar insulins in Europe (English)

1 reference

5 November 2017

7 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

15 August 2020

27 October 2020

13 November 2020

1 reference

17 November 2019

1 reference

20 November 2019

1 reference

15 August 2020

anti-diabetic medication

1 reference

27 October 2020

1 reference

13 November 2020

1

1 reference

PubMed publication ID

11 September 2017

D Dahl

2

1 reference

5 November 2017

T Heise

series ordinal

3

1 reference

5 November 2017

J Kiljanski

series ordinal

4

1 reference

5 November 2017

C Mathieu

series ordinal

5

1 reference

5 November 2017

13 June 2017

1 reference

5 November 2017

1 October 2017

7 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

15 August 2020

27 October 2020

13 November 2020

8 references

5 November 2017

14 March 2019

24 March 2019

17 November 2019

20 November 2019

15 August 2020

27 October 2020

13 November 2020

34

1 reference

5 November 2017

10

1 reference

5 November 2017

1340-1353

1 reference

Creative Commons Attribution-NonCommercial-NoDerivatives

5 November 2017

7 references

14 March 2019

24 March 2019

17 November 2019

20 November 2019

15 August 2020

27 October 2020

13 November 2020

on focus list of Wikimedia project

0 references

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Interchangeability among reference insulin analogues and their biosimilars: regulatory framework, study design and clinical implications.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Development and regulation of biosimilars: current status and future challenges.

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

The emergence of biosimilar insulin preparations--a cause for concern?

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

15 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5637898

21 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28608570

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28608570

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28608570

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/DME.13400

1 reference

5 November 2017

1 reference

5 November 2017

PubMed publication ID

28608570

1 reference